A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan

Internal Medicine

Volumn 46, Issue 4, 2007, Pages 157-162

  Tsutani, Kiichiro ^a   Igarashi, Ataru ^a   Fujikawa, Keita ^b   Evers, Thomas ^c   Kubin, Maria ^c   Lamotte, Mark ^d   Annemans, Lieven ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b BAYER YAKUHIN LTD   (Japan)

^c Product Development Division   (Germany)

^d HEDM   (Belgium)

Author keywords

Aspirin; Pharmacoeconomics analysis; Primary prevention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ANAMNESIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEALTH ECONOMICS; HEALTH INSURANCE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; JAPAN; LOW DRUG DOSE; META ANALYSIS; MORTALITY; PREDICTION; PRIMARY PREVENTION; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

ADULT; AGED; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EVALUATION STUDIES; FEMALE; HEALTH CARE COSTS; HUMANS; JAPAN; MALE; MARKOV CHAINS; MIDDLE AGED; PRIMARY PREVENTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 33847046736     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.1843     Document Type: Article

References (12)

1. Kokumin-Iryohi-no-Gaikyo (National Medical Care Expenditure 2003) http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/03/index.htm]. (in Japanese).
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339, 1996.
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86, 2002 (Erratum in: BMJ 324: 141, 2002).
4. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136: 161-172, 2002.
5. Eidelman RS, Herbert PR, Weisman SM, Hennekens CH. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med 163: 2006-2010, 2003.
6. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106 (3): 388-391, 2002.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24: 1601-1610, 2003.
8. Lamotte M, Annemans L, Evers T, et al. A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. Pharmacoeconomics 24: 155-169, 2006.
9. Ishikawa BK, Matsuda S. Kyu-sei-ki Nyu-in Iryo Shiko Shin-dan Bunrui (Survey using Diagnostic and Procedure Combination). Number H13-SEISAKU-034, Supple 3-1, 2004 (in Japanese).
10. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the pimary prevention of cardiovascular disease in women. N Engl Med J 352: 1293-1304, 2005.
11. Kanjya-Chosa 2002 (Patient Survey 2002). http://www.mhlw.go.jp/toukei/ itiran/gaiyo/k-eisei.html (in Japanese).
12. Shakai-Iryo Shinryo-koi-betsu Chosa 2002 (Survey of National Medical Care Insurance Service 2002). http://www.mhlw.go.jp/toukei/saikin/hw/ sinryo/tyosa02/index.html. (in Japanese).